Cargando…

Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling

Diabetes is a metabolic disease characterized by chronic hyperglycemia. Polygenic diabetes, which encompasses type-1 and type-2 diabetes, is the most prevalent kind of diabetes and is caused by a combination of different genetic and environmental factors, whereas rare phenotype monogenic diabetes is...

Descripción completa

Detalles Bibliográficos
Autores principales: Dabi, Yosef Tsegaye, Degechisa, Sisay Teka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199525/
https://www.ncbi.nlm.nih.gov/pubmed/35719247
http://dx.doi.org/10.2147/DMSO.S366967
_version_ 1784727857827676160
author Dabi, Yosef Tsegaye
Degechisa, Sisay Teka
author_facet Dabi, Yosef Tsegaye
Degechisa, Sisay Teka
author_sort Dabi, Yosef Tsegaye
collection PubMed
description Diabetes is a metabolic disease characterized by chronic hyperglycemia. Polygenic diabetes, which encompasses type-1 and type-2 diabetes, is the most prevalent kind of diabetes and is caused by a combination of different genetic and environmental factors, whereas rare phenotype monogenic diabetes is caused by a single gene mutation. Monogenic diabetes includes Neonatal diabetes mellitus and Maturity-onset diabetes of the young. The majority of our current knowledge about the pathogenesis of diabetes stems from studies done on animal models. However, the genetic difference between these creatures and humans makes it difficult to mimic human clinical pathophysiology, limiting their value in modeling key aspects of human disease. Human pluripotent stem cell technologies combined with genome editing techniques have been shown to be better alternatives for creating in vitro models that can provide crucial knowledge about disease etiology. This review paper addresses genome editing and human pluripotent stem cell technologies for in vitro monogenic diabetes modeling.
format Online
Article
Text
id pubmed-9199525
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-91995252022-06-16 Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling Dabi, Yosef Tsegaye Degechisa, Sisay Teka Diabetes Metab Syndr Obes Review Diabetes is a metabolic disease characterized by chronic hyperglycemia. Polygenic diabetes, which encompasses type-1 and type-2 diabetes, is the most prevalent kind of diabetes and is caused by a combination of different genetic and environmental factors, whereas rare phenotype monogenic diabetes is caused by a single gene mutation. Monogenic diabetes includes Neonatal diabetes mellitus and Maturity-onset diabetes of the young. The majority of our current knowledge about the pathogenesis of diabetes stems from studies done on animal models. However, the genetic difference between these creatures and humans makes it difficult to mimic human clinical pathophysiology, limiting their value in modeling key aspects of human disease. Human pluripotent stem cell technologies combined with genome editing techniques have been shown to be better alternatives for creating in vitro models that can provide crucial knowledge about disease etiology. This review paper addresses genome editing and human pluripotent stem cell technologies for in vitro monogenic diabetes modeling. Dove 2022-06-11 /pmc/articles/PMC9199525/ /pubmed/35719247 http://dx.doi.org/10.2147/DMSO.S366967 Text en © 2022 Dabi and Degechisa. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Dabi, Yosef Tsegaye
Degechisa, Sisay Teka
Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling
title Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling
title_full Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling
title_fullStr Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling
title_full_unstemmed Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling
title_short Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling
title_sort genome editing and human pluripotent stem cell technologies for in vitro monogenic diabetes modeling
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199525/
https://www.ncbi.nlm.nih.gov/pubmed/35719247
http://dx.doi.org/10.2147/DMSO.S366967
work_keys_str_mv AT dabiyoseftsegaye genomeeditingandhumanpluripotentstemcelltechnologiesforinvitromonogenicdiabetesmodeling
AT degechisasisayteka genomeeditingandhumanpluripotentstemcelltechnologiesforinvitromonogenicdiabetesmodeling